Added to YB: 2026-05-05
Pitch date: 2026-05-01
TEVA [bullish]
Teva Pharmaceutical Industries Limited
+1.35%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$41.2B
Pitch Price
$103.60
Price Target
60.00 (-43%)
Dividend
N/A
EV/EBITDA
10.55
P/E
26.42
EV/Sales
3.13
Sector
Pharmaceuticals
Category
turnaround
Teva ($TEVA): The Pivot to Growth is delivering a re-rate
TEVA: Q1 rev $4B (-1% USD, +7% ex-Japan/REVLIMID). Branded portfolio (AUSTEDO, AJOVY, UZEDY) +41% YoY, driving gross margin to 52.9%. Net debt/EBITDA 2.42x (down from 3.10x), targeting <2.0x in 2027 for investment grade. Acquired Emalex for $700M upfront: ecopipam (Tourette's) has positive Ph3, NDA H2'26, $70-130K pricing potential, 7yr exclusivity. AUSTEDO path to $3B peak sales, UZEDY fastest-growing LAI. 11 biosimilars on market, targeting $16B originator sales by 2027. FCF guide $2.0-2.4B. Fair value $40-42 near-term, $58-60 in 3yrs on mix shift & re-rating.
Read full article (5 min)